Clinical trialNCT04471415TerminatedPhase 1/PHASE2Interventional

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

SponsorDracen Pharmaceuticals, Inc.Enrollment61Advanced Solid TumorNon Small Cell Lung Cancer Metastatic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous injection as a single agent and in combination with atezolizumab in patients with advanced solid tumors and to assess preliminary safety and efficacy of which route of administration (intravenous or subcutaneous) will be selected for further development for the one expansion of patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Sunil Sharma, MD
HonorHealth Director
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Germany

Centrum Fur Integrieerte Onkologie
Cologne, Germany
University Cancer Center Nct
Dresden, Germany
University Hospital Frankfurt
Frankfurt, Germany
University Klinikum Wuerzburg
Würzburg, Germany

Singapore

National Cancer Center Singapore
Singapore, Singapore

Spain

Hospital University Vall D'Hebron
Barcelona, Spain
University Hospital 12 de Octubre
Madrid, Spain

Taiwan

National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan

United States

Honorhealth
Scottsdale, Arizona, United States
Ucla
Los Angeles, California, United States
Adventhealth Medical Group
Kissimmee, Florida, United States
Florida Cancer Specialist
Orlando, Florida, United States
Johns Hopkins Kimmel Institute
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Nyu Langone
New York, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Next Oncology
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DRP-104Atezolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2020
Primary completion: 28 Mar 2023
Completion: 28 Mar 2023
Last update posted: 12 Jun 2023
Registered enrollment: 61
Registry id: NCT04471415

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-002770-27

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.